Marianna Mancini - Jul 29, 2024 Form 4 Insider Report for Viking Therapeutics, Inc. (VKTX)

Role
Chief Operating Officer
Signature
/s/ Michael Morneau as Attorney-in-Fact
Stock symbol
VKTX
Transactions as of
Jul 29, 2024
Transactions value $
-$1,029,912
Form type
4
Date filed
7/31/2024, 04:05 PM
Previous filing
May 2, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +10K +2.87% $0.00 359K Jul 29, 2024 Direct F1
transaction VKTX Common Stock, par value $0.00001 per share Award $0 +21.7K +6.04% $0.00 380K Jul 29, 2024 Direct F2
transaction VKTX Common Stock, par value $0.00001 per share Sale -$838K -14.7K -3.87% $56.98 365K Jul 30, 2024 Direct F3, F4
transaction VKTX Common Stock, par value $0.00001 per share Sale -$192K -3.32K -0.91% $57.82 362K Jul 30, 2024 Direct F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported securities were subject to a performance restricted stock unit award that was granted on January 4, 2021, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
F2 The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2024, 33.33% of which vested on July 29, 2024 upon the achievement of a non-financial performance goal.
F3 These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to certain performance restricted stock unit awards.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.48 to $57.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.51 to $58.49, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.